<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20040210104927+01'00'</creation_date><modification_date>D:20040210104927+01'00'</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-00-131_h_w_dec_13.pdf</pdf_file></head><body><section><header>en  
   en</header></section><section><header>en</header><p>commission of the european communities</p><p>brussels, 05-02-2004 c(2004) 412 
 not for publication</p></section><section><header>commission decision of 05-02-2004 
 amending the marketing authorisation for &quot;pegintron - peginterferon alfa-2b&quot;, a 
 medicinal product for human use, granted by decision c(2000)1407 
 (text with eea relevance)</header><p>only the french and the dutch texts are authentic</p></section><section><header>en  
   en</header></section><section><header>commission decision of 05-02-2004 
 amending the marketing authorisation for &quot;pegintron - peginterferon alfa-2b&quot;, a 
 medicinal product for human use, granted by decision c(2000)1407 
 (text with eea relevance)</header><p>the commission of the european communities,</p><p>having regard to the treaty establishing the european community,</p><p>
 having regard to council regulation (eec) no 2309/93 of 22 july 1993 laying down 
 community procedures for the authorization and supervision of medicinal products for 
 human and veterinary use and establishing a european agency for the evaluation of 
 medicinal products
 1, having regard to commission regulation (ec) no 542/95 of 10 march 1995 concerning 
 the examination of variations to the terms of a marketing authorisation falling within the 
 scope of council regulation (eec) no 2309/93
 2, and in particular article 8(3) thereof,</p><p>having regard to the application submitted by schering plough europe on 19 september 
 2003 under article 6(1) of commission regulation (eec) no 542/95,</p><p>
 having regard to commission regulation (ec) no 1085/2003 of 3 june 2003 concerning 
 the examination of variations to the terms of a marketing authorisation for medicinal 
 products for human use and veterinary medicinal products falling within the scope of 
 council regulation (eec) no 2309/93
 3, and in particular article 6(10) thereof,</p><p>having regard to the opinion of the european agency for the evaluation of medicinal 
 products, formulated by the committee for proprietary medicinal products on 20 
 november 2003,</p><p>
 whereas:</p><p>
 (1)</p><p>an examination of the variations to the terms of the marketing authorisation for 
 the medicinal product &quot;pegintron - peginterferon alfa-2b&quot;, entered in the 
 community register of medicinal products under nos eu/1/00/131/001-050 and 
 authorised by commission decision c(2000)1407 of 25 may 2000, has shown 
 that the product still complies with the requirements set out in directive</p><p>
 1 oj l 214, 24.8.1993, p. 1. regulation as amended by commission regulation (ec) no 649/98 (oj l 88, 24.3.1998, p. 7). 
 2 oj l 55, 11.3.1995, p. 15, as amended by regulation (ec) no 1069/98 (oj l 153, 27.5.1998, p. 11). 3 oj l 159, 27.6.2003, p. 24.</p></section><section><header>en  
   en</header><p>2001/83/ec of the european parliament and of the council of 6 november 2001 on the community code relating to medicinal products for human use
 4. (2)</p><p>the application to modify the authorisation and to amend decision c(2000)1407 
 accordingly should be accepted.</p><p>
 has adopted this decision:</p><p>
 article 1</p><p>decision c(2000)1407 is amended as follows:</p><p>
 1. annex i is replaced by the text set out in annex i to this decision;</p><p>
 2. annex iii b is replaced by the text set out in annex ii to this decision.</p><p>
 article 2</p><p>this decision is addressed to schering plough europe, rue de stalle, 73, 1180 bruxelles, belgique – stallestraat, 73 – 1180 brussel, belgië.</p><p>
 done at brussels, 05-02-2004</p><p>
 for the commission erkki liikanen 
 member of the commission</p><p>4 oj l 311, 28.11.2001, p. 67. directive as last amended by</p><p>directive 2003/63/ec (oj l 159, 27.6.2003, p. 46).</p></section></body></xml>